On April 19, 2023 Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, announces encouraging preclinical proof of concept data at a poster presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2023 Annual Meeting being held April 14 – 19, 2023 in Orlando, Florida (Press release, Actinium Pharmaceuticals, APR 19, 2023, View Source [SID1234630322]). The poster showcased the robust anti-tumor effects of HER3-targeted radiotherapy using multiple therapeutic radionuclides in preclinical models of high unmet need malignancies.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Highlights from the AACR (Free AACR Whitepaper) poster titled, "Novel HER3 targeting antibody radioconjugates, 225Ac-HER3 ARC and 177Lu-HER3 ARC, exhibit potent antitumor efficacy in HER3-positive solid tumors" include:
Actinium’s HER3-targeted radiotherapy displayed strong anticancer activity when conjugated to either alpha-emitting Actinium-225 or beta-emitting Lutetium-177 in models of two high unmet need cancers, highlighting its therapeutic potential for HER3+ malignancies
HER3-ARC showed strong target engagement and efficient cellular internalization with compelling cytotoxic activity against established in vitro cellular models
A single dose of HER3-ARC, conjugated to either Actinium-225 (p<0.0001) or Lutetium-177 (p<0.0001) showed highly significant reductions in tumor burden in a preclinical ovarian cancer model compared to bevacizumab, an anti-VEGF monoclonal antibody indicated in ovarian cancer
Promising antitumor activity displayed in a preclinical model of colorectal cancer, a highly aggressive malignancy, including a significant reduction in tumor volume (p<0.0001) when dosed with 225Ac-HER3-ARC
The consistent overexpression of HER3 in multiple solid tumor types including ovarian, renal, prostate, urothelial, breast, and lung cancers suggests broad utility of a HER3-targeted agent across oncology indications
"Actinium is committed to developing targeted radiotherapies for patients with unmet needs and our program targeting HER3, a validated, pan-cancer target, is a strong representation of our R&D capabilities", said Sandesh Seth, Actinium’s Chairman and CEO. "The new data from our HER3 program once again demonstrate the potent anti-tumor effect and broad utility of targeted radiotherapy in solid tumors. Building on our prior results in lung cancer models, we are excited by the highly significant reduction in tumor burden seen in ovarian cancer and colorectal cancer models, providing much improved treatment options to critical patients with poor clinical outcomes. These data also demonstrate our isotope-agnostic approach to targeted radiotherapy development enabling us to generate optimal therapies, given our strong, industry leading clinical experience with both beta and alpha therapies."
HER3 is a member of the EGFR family, a highly validated cancer target for which there are several approved therapies directed against EGFR and/or HER2. However, there are no approved therapeutics targeting HER3, which is upregulated in response to EGFR and HER2 therapies as part of acquired resistance and is associated with poor survival in multiple solid tumors including breast, colorectal, lung, ovarian and others.
The poster will be available on the presentations page of Actinium’s investor relations page of its website: View Source